NeuBase Therapeutics, Inc.
Company Snapshot: NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc., a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
- Sep 28 2021 NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference
- Sep 15 2021 NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
- Sep 14 2021 NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer
- Sep 1 2021 NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference